

Remarks

The specification has been amended to cross-reference related applications.

An abstract is provided on a separate sheet enclosed herewith.

Claims 4, 6-25, 30-35 and 39-42 are in the case.

Multiple dependent claims have been eliminated.


Use claims 19-24 have been converted to method claims.

Claims 39-42 are new claims. Support for new Claim 39 is found in the enclosed specification at page 16, lines 21-28. Support for new Claims 40-42 and support for the amendment to Claim 24 are found in the enclosed specification at page 18, line 13-page 23, line 34.

A copy of the International Preliminary Examination Report is being submitted herewith or will be submitted; please note that the International Examiner is satisfied that the subject matter of PCT Claims 1-38 is both novel and inventive over the references cited in the International Search Report.

Respectfully submitted,

BACON & THOMAS, PLLC

By: 
Eric S. Spector
Reg. No. 22,495

BACON & THOMAS, PLLC
625 Slaters Lane, Fourth Floor
Alexandria, Virginia 22314
703 683 0500

Case: P9642 US-W0
B&T Docket No. SPEI3002

ABSTRACT

Controlled Release Composition

5

An improved composition for controlling the release profile of an active compound through the intestinal tract comprises particles, especially pellets, containing the active compound, which are coated with a pH dissolution dependent coating material or a
10 polymethacrylate material, which is preferably pH dissolution dependent, to a certain thickness depending upon the location and rate of release of the active compound that is desired. In preferred compositions, two
15 or more pluralities of particles, in which particles of each plurality are coated with pH dissolution dependent coating material or polymethacrylate material to a different thickness to those of each other plurality, are contained within an enterically coated capsule and
20 provide release of the active compound at various desired locations in the intestinal tract.

25

30

(Figure 1)